
    
      This is a randomized (study drug assigned by chance), double-blind (neither the physician nor
      the patient knows the name of the assigned drug) study to evaluate the safety and
      effectiveness of different doses of JNJ-42160443 compared with placebo in the treatment of
      patients with a diagnosis of chronic low back pain who have moderate to severe, chronic low
      back pain that is not controlled by standard pain medications. JNJ-42160443 (10 mg/ml) or
      matching placebo given as a subcutaneous (SC) (under the skin) injection (inj) once every 4
      weeks (wks); one of four JNJ-42160443 doses (1 mg every 4 wks; 3 mg every 4 wks; 6 mg loading
      dose on Day 1 followed by 3 mg every 4 wks; or 10 mg every 4 wks, or matching placebo for up
      to 104 wks (12-wk double-blind efficacy period + 92-wk double-blind extension period).
    
  